Valuation: Design Therapeutics, Inc.

Market Cap 597M 544M 501M 456M 855M 55.27B 898M 6.1B 2.42B 30.19B 2.24B 2.19B 94.74B P/E 2026 *
-7x
P/E 2027 * -5.84x
Enterprise Value 405M 369M 340M 309M 580M 37.53B 610M 4.14B 1.65B 20.5B 1.52B 1.49B 64.33B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
68.86%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Design Therapeutics, Inc.

1 day-3.00%
1 week-13.37%
Current month-15.07%
1 month-18.29%
3 months-41.71%
6 months-18.29%
Current year-3.30%
1 week 9.02
Extreme 9.02
10.46
1 month 9.02
Extreme 9.02
11.42
Current year 8.23
Extreme 8.23
17.25
1 year 7.82
Extreme 7.8201
17.25
3 years 2.13
Extreme 2.13
17.25
5 years 1.94
Extreme 1.94
26.3
10 years 1.94
Extreme 1.94
50.5
Manager TitleAgeSince
Chief Executive Officer 56 25/08/2023
Chief Tech/Sci/R&D Officer 60 17/04/2025
Chief Tech/Sci/R&D Officer - 01/02/2025
Director TitleAgeSince
Chairman 56 18/12/2017
Director/Board Member 71 01/07/2019
Director/Board Member 49 01/02/2020
Date Insider Type Main position Quantity % Market Cap. Importance
3/31/26 A Free

Director

67,500 0.1185%
1/2/26 A Free

Chief Executive Officer

750,000 1.3166%
1/2/26 A Free

Director

45,000 0.0790%
Change 5-day change 1-year change 3-year change Capi.($)
-2.95%-13.37%+15.25%+306.73% 597M
-2.49%-6.35%+51.07%+64.95% 65.42B
-0.63%-2.91%+6.20%+89.22% 58.91B
-2.37%-2.22%+22.87%+82.31% 55.24B
-2.01%-5.75%+12.40%+108.97% 45.66B
-1.46%-6.65%+13.99%+20.56% 41.29B
-0.93%+1.67%+20.83%+45.03% 36.82B
+1.32%-6.31%+130.98%+642.80% 34.48B
-0.80%+0.61%+77.26%+56.26% 32.5B
-1.81%+17.42%-28.74%+477.86% 31.69B
Average -1.38%-1.78%+32.21%+189.47% 40B
Weighted average by Cap. -1.34%-1.29%+32.31%+151.15%

Financials

2026 *2027 *
Net sales - -
Net income -83.32M -75.88M -69.92M -63.6M -119M -7.72B -125M -851M -338M -4.21B -313M -306M -13.23B -113M -103M -95.24M -86.63M -163M -10.51B -171M -1.16B -461M -5.74B -426M -417M -18.01B
Net Debt -192M -174M -161M -146M -274M -17.74B -288M -1.96B -778M -9.69B -719M -704M -30.41B -182M -166M -153M -139M -261M -16.89B -274M -1.86B -740M -9.22B -684M -670M -28.95B
Projected Income Statement - Annual - Design Therapeutics, Inc.
Logo Design Therapeutics, Inc.
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Employees
60
Date Price Change Volume
20/11/26 $9.070 -2.68% 124,090
19/11/26 $9.320 -1.58% 266,861
18/11/26 $9.470 -3.76% 319,965
17/11/26 $9.840 -0.81% 294,391
16/11/26 $9.920 -5.25% 301,609
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Design Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
9.320USD
Average target price
21.57USD
Spread / Average Target
+131.45%
  1. Stock Market
  2. Stocks
  3. DSGN Stock